Sam Matthews

A Victorian construction company is seeking indemnity costs against the company that unsuccessfully pursued a winding-up application against it, as well as a personal costs order against its director.

Baker McKenzie’s IP litigation practice has received a shot in the arm, with the firm nabbing a partner from Clayton Utz who has several successful trips to the High Court under his belt, along with two members of his team.

The Fair Work Commission has found that a software company did not unfairly dismiss an employee over his non-compliance with a directive to return to the office, saying that a remote work clause in his employment contract was conditional.

A court has ruled that the body corporate of a block of units can bring a contract claim against builder Devine in its own name, finding that parliament did not intend to import the technical legal meaning of ‘subrogation’ into legislation governing owners corporations.

A court has slapped Qoin cryptocurrency issuer BPS Financial with a $14 million penalty for “serious and unlawful misconduct”, including making misleading statements about the product and providing financial advice without a license.

V2food, the CSIRO-backed start-up behind Hungry Jack's plant-based 'Rebel Whopper', has lost its bid to patent a product that changes colour when cooked in order to imitate the “meat experience”.

Perth law firm Lavan has moved its offices to a newly-built high rise in Elizabeth Quay, joining high-profile tenants, including Multiplex, at the prime waterfront site.

Sustainability reporting technology company Noviqtech is set to acquire biochar carbon dioxide removal company Coralia, which aims to mitigate AI-related carbon emissions.

A court has agreed to hear the Parramatta Eels’ case against former player Zac Lomax on an expedited basis, as the club seeks to enforce a contractual term keeping him off the list of rival teams after an unsuccessful mediation with the Melbourne Storm.  

AstraZeneca has sued Pharmacor over its plans to list a generic version of blockbuster diabetes drug Forxiga on the PBS, but the drug maker will have to defend the validity of the patent, which was struck down by a UK court last year.